David Morris, MD, FACS, of Urology Associates of Nashville, discusses the emerging role of copper-based PSMA imaging agents, specifically Clarity Pharmaceuticals’ 64Cu-SAR-bisPSMA, in prostate cancer diagnostics.
He highlights the unique dual-binding structure of this tracer, which may offer increased sensitivity and specificity compared to gallium-based PSMA tracers. The conversation explores the clinical benefits of same-day and next-day imaging, which allows for more flexible scheduling and may enhance detection of smaller nodal metastases.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.